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A B S T R A C T
Extracellular vesicles (EVs) generated from redox active anticancer drugs are released into the extracellular
environment. These EVs contain oxidized molecules and trigger inflammatory responses by macrophages. Using
a mouse model of doxorubicin (DOX)-induced tissue injury, we previously found that the major sources of
circulating EVs are from heart and liver, organs that are differentially affected by DOX. Here, we investigated the
effects of EVs from cardiomyocytes and those from hepatocytes on macrophage activation. EVs from H9c2 rat
cardiomyocytes (H9c2 EVs) and EVs from FL83b mouse hepatocytes (FL83 b EVs) have different levels of pro-
tein-bound 4-hydroxynonenal and thus different immunostimulatory effects on mouse RAW264.7 macrophages.
H9c2 EVs but not FL83 b EVs induced both pro-inflammatory and anti-inflammatory macrophage activation,
mediated by NFκB and Nrf-2 pathways, respectively. DOX enhanced the effects of H9c2 EVs but not FL83 b EVs.
While EVs from DOX-treated H9c2 cells (H9c2 DOXEVs) suppressed mitochondrial respiration and increased
glycolysis of macrophages, EVs from DOX-treated FL83b cells (FL83b DOXEVs) enhanced mitochondrial reserve
capacity. Mechanistically, the different immunostimulatory functions of H9c2 EVs and FL83 b EVs are regulated,
in part, by the redox status of the cytoplasmic thioredoxin 1 (Trx1) of macrophages. H9c2 DOXEVs lowered the
level of reduced Trx1 in cytoplasm while FL83b DOXEVs did the opposite. Trx1 overexpression alleviated the
effect of H9c2 DOXEVs on NFκB and Nrf-2 activation and prevented the upregulation of their target genes. Our
findings identify EVs as a novel Trx1-mediated redox mediator of immune response, which greatly enhances our
understanding of innate immune responses during cancer therapy.
1. Introduction
Extracellular vesicles (EVs), small membrane-encapsulated struc-
tures that are released by most cell types as alternative pathways,
maintain cellular homeostasis by removing toxic oxidized molecules.
Accumulating evidence has revealed the important role of EVs in
mediating intercellular communication in the presence of local and
systemic inflammation that results from such oxidative stresses as
aging, cancer, cardiovascular diseases and lung diseases [1–5]. EVs can
suppress or activate immune response depending on the bioactive
contents of the EVs. The immunostimulatory effects of EVs are influ-
enced by the transfer of damage-associated molecular patterns (DAMPs)
from damaged cells and activate immune cells [6–9]. In contrast, the
immunoinhibitory effects of EVs are associated with the transfer of
immunomodulatory transcription factors, non-coding RNAs, and anti-
inflammatory cytokines, most of which are released from cancer cells
and stem cells [10].
Macrophages are mononuclear phagocytic cells that mediate an
innate immune response by recognizing microbial and endogenous
danger-signaling molecules [11]. Macrophages are activated in re-
sponse to environmental stimuli and produce distinct sets of cytokines,
as well as enhance or inhibit inflammation by changing cellular meta-
bolism. In physiologic conditions, the balance of the pro- and anti-in-
flammatory activities of macrophages is strictly regulated. A balanced
response is critical for containment or elimination of pathogens. Severe
pro-inflammatory immune response leads to secondary cytotoxicity and
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tissue destruction, and excessive anti-inflammatory response leads to
tissue fibrosis.
Doxorubicin (DOX) is one of the most effective chemotherapeutic
agents for treating many aggressive malignancies [12]. However, its
efficacy is limited by severe side effects to normal tissues that result
primarily from its redox capacity [13]. DOX can cause both direct and
indirect tissue injuries: the drug has a direct effect on target tissues as
well as indirect effects that result from systemic inflammation initiated
by an innate immune response. For example, the migration of circu-
lating inflammatory cytokines into an organ such as the brain leads to
secondary tissue damage known as chemotherapy-induced cognitive
impairment or chemobrain [14]. This influence is different from effects
caused by cellular penetration by the drug.
4-hydroxynonenal (4HNE) is the most toxic lipid peroxidation
product generated during DOX-induced oxidative stress [15]. The ef-
fects of 4HNE are primarily due to covalent modification of amino acids
that contain a nucleophilic functional group, such as lysine, histidine,
and cysteine, leading to inactivation or functional change of the ad-
ducted proteins [16]. That 4HNE induces a toxic effect that leads to
cardiac injury following DOX treatment is well-established. Adducts of
4HNE to the proteins involved in the mitochondrial electron transport
chain in DOX-treated heart tissues are formed, which results in mi-
tochondrial dysfunction [17]. Furthermore, 4HNE adduction to mi-
tochondrial apoptotic inducing factor 2 (AIFm2) can change AIFm2
function from oxidoreductase to pro-apoptosis and mediate cardio-
myocyte cell death [18]. Our previous study demonstrates that serum
EVs of mice treated with DOX were 4HNE-adducted. Also, we identified
heart and liver tissues as the major contributors to oxidized EVs [19].
However, the heart and liver are differentially susceptible to DOX
toxicity. While cardiac injury is a well-known long-term side effect of
DOX, liver injury is rarely observed in DOX-treated patients [20]. The
reason for this might be that enrichment of antioxidant enzymes [21]
and drug transporters [22] protect liver from oxidative damage. How-
ever, how EVs impact immune cells has never been investigated. Here,
we hypothesize that the EVs released from cardiomyocytes and hepa-
tocytes exposed to DOX may have differential effects on macrophage
activation, which would lead to differences in secondary tissue injury.
Thioredoxin (Trx) is a small redox-sensitive protein that contains
two redox-active cysteine residues—Cys-32 and Cys-35—in its active
site. Trx maintains the reducing environment of the cells by a thiol-
disulfide exchange [23] and a denitrosylation reaction [24]. Trx1
overexpression, as well as administration of recombinant Trx1, is pro-
tective against severe inflammatory diseases, including inflammatory
bowel disease [25], pancreatitis [26], and sepsis [27]. However, the
role of Trx1 in EVs-mediated innate immune response is unknown.
In macrophages, Trx1 regulates immune activation by interacting
with several proteins. Depending on cellular localization, Trx1 has the
dichotomous functions of regulating two opposing redox-sensitive im-
munomodulatory transcription factors: nuclear factor kappa-light-
chain-enhancer of activated B cells (NFκB) and nuclear factor
(erythroid-derived 2) like 2 (Nrf-2). NFκB is responsible for pro-in-
flammatory cytokines, chemokines, and adhesion molecules, whereas
Nrf-2 drives anti-inflammatory response by upregulating anti-oxidant
gene expression [28,29] and also by directly interfering with pro-in-
flammatory cytokine gene transcription [30]. Cytosolic Trx1 prevents
dissociation of IκB from NFκB [31] and also directly interacts with the
Nrf-2 interacting protein, Kelch-like ECH-associated protein-1 (Keap-1),
maintaining KEAP1 in a reduced state [32] and thus blocking NFκB and
Nrf-2 nuclear translocation, respectively. However, should NFκB or Nrf-
2 translocate into the nucleus, Trx1 can promote its transcriptional
activity by maintaining it in a reduced state [33,34].
In this study, we tested the hypothesis that cardiomyocytes and
hepatocytes release EVs with different oxidized protein levels in re-
sponse to DOX treatment, as exemplified by 4HNE protein adduction,
and that they have differential effects on macrophages. We found that
Trx1 regulates EV-induced macrophage activation by controlling the
redox-sensitive transcription factors NFκB and Nrf-2. The findings of
this study provide an insight into the intercellular communication be-
tween oxidatively injured cells and macrophages, and suggest a new
therapeutic intervention to prevent DOX-induced inflammation.
2. Materials and methods
2.1. Cell culture
H9c2 rat cardiomyocyte, FL83b mouse hepatocyte, RAW264.7
mouse macrophage, and NR8383 rat macrophage cell lines were ob-
tained from American Type Culture Collection (Manassas, VA). H9c2
and FL83b are immortalized normal cells from heart and liver, re-
spectively. H9c2 cells were maintained in DMEM low glucose supple-
mented with 10% FBS, 1% penicillin/streptomycin, 1mM pyruvate,
25mM HEPES, 2mM L-glutamine, and 1% non-essential amino acids.
FL83b cells were maintained in F12 medium supplemented with 10%
FBS and 1% penicillin/streptomycin. RAW264.7 cells were maintained
in DMEM high glucose supplemented with 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin. NR8383 cells were maintained
in Ham's F12K medium supplemented with 15% heat inactivated FBS,
2mM L-glutamine, and 1.5 g/L sodium bicarbonate. The absence of
mycoplasma contamination was confirmed in all cell lines.
2.2. Cell viability test
The sensitivity of H9c2 and FL83b cells to DOX toxicity was mea-
sured by the MTT assay. This assay relies on electron transfer from
NADH and NADPH to MTT, which is achieved by oxidoreductase en-
zyme activity in viable cells [35]. The final product is an insoluble
purple colored formazan. In this experiment, H9c2 or FL83b cells were
seeded in 96-well plates at the density of 1000 cells/well. The next day
the cells were exposed to 0.5 μM of DOX for 24 h. Cells were then
washed with PBS, and 30 μl of MTT solution (5mg/ml in PBS) were
Abbreviations
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FL83b NTEVs Non-treated FL83b hepatocyte-derived EVs
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added to each well and incubated for 1 h. Then, 70 μl of 50% DMSO and
50% SDS were added to solubilize the formazan crystals. Absorbance
was determined at 540 nm by SpectraMax Plus 384 microplate reader
(Molecular Devices, San Jose, CA). DOX cytotoxicity was expressed as
the percent of viability in treated cells relative to the non-treated
control.
2.3. EV isolation and quantification
H9c2 and FL83b were treated or not treated with 0.5 μM DOX for 1
h followed by washing three times with 10ml PBS. The media were
changed to an EVs-free growing medium and incubated for 48 h before
the conditioned media were collected. The conditioned media were
filtered through 0.8 μm syringe filters to exclude vesicles larger than
0.8 μm, which are typically the apoptotic bodies. The filtered condi-
tioned media were stored at −80 °C. The frozen conditioned media
were thawed at room temperature before starting the EV isolation
process.
EVs were isolated by an affinity-based membrane method using
exoEasy maxi kit (Qiagen, Hilden, Germany) according to the manu-
facturer's instructions. All types of EVs, including exosomes, micro-
vesicles, and apoptotic bodies, were bound to the spin column and
eluted to obtain EV products. The conditioned media were thawed at
room temperature, and 32ml of the media were then mixed 1:1 with
the binding buffer XBP and applied onto the affinity spin column al-
lowing EVs to bind to the membrane. After centrifugation at 500×g for
1min, the flow-through was discarded. Washing buffer XWP was added
to the column and centrifuged at 5000×g for 5min to wash off con-
taminating proteins and residual buffer. Buffer XE was then applied
onto the membrane and centrifuged at 500×g for 5min to elute EVs
from the column. The elution was applied to the column again and
centrifuged at 5000×g for 5min. Since XE buffer contains primarily
inorganic salts that are toxic to cells, buffer exchanges with PBS were
performed using 3 kDa Amicon Ultra-15 Centrifugal Filter units
(Millipore Sigma, Burlington, MA). The amount of EVs was evaluated
by bicinchoninic acid assay (Thermo Fisher Scientific, Waltham, MA).
The EVs were stored at −80 °C until used.
2.4. 4HNE adducted protein measurement
EVs from non-treated H9c2 (H9c2 NTEVs), DOX-treated H9c2
(H9c2 DOXEVs), non-treated FL83b (FL83b NTEVs), and DOX-treated
FL83b (FL83b DOXEVs) cells were lysed with radio-
immunoprecipitation assay (RIPA) buffer and mixed with an equal
volume of Laemmli buffer. Equivalent protein samples (250 ng) were
then loaded on nitrocellulose membrane using Bio-Dot SF microfiltra-
tion apparatus (Bio-Rad). The membranes were left to air dry overnight.
The next day, the membranes were blocked with blocking buffer for 2 h
followed by incubation with anti-4HNE antibody (1:5000 dilution) for
1 h on an orbital shaker. After washing with TBST three times, the
membranes were incubated with IRDye® 800CW donkey anti-rabbit
(1:15,000 dilution) for 1 h. Then, the membranes were washed and left
to air dry. The 4HNE-adducted protein bands were visualized using an
Odyssey scanner (LI-COR).
2.5. Multiplex Cytokines Array
For macrophage activation, RAW264.7 cells were seeded at a den-
sity of 5×105 cells/well in a 6 well-plate overnight and incubated with
FBS-free media supplemented with 20 μg of H9c2 NTEVs, H9c2
DOXEVs, FL83b NTEVs, FL83b DOXEVs, or an equal volume of PBS as
the vehicle for 24 h. The conditioned media were then collected and
were frozen at −80 °C until used. V-PLEX mouse cytokine immunoassay
kit (Meso Scale Diagnostics, Rockville, MD) was used to measure TNF
alpha, IL-1 beta, IL-6, and IL-10. Mouse TGF-beta 1 DuoSet ELISA (R&D
Systems, Minneapolis, MN) was used to measure TGF- beta 1. All assays
were performed according to manufacturers’ protocols. All standards
and samples were measured in duplicate or triplicate.
2.6. Nitric oxide (•NO) measurement
RAW264.7 cells were treated with FBS-free DMEM without phenol
red and supplemented with 20 μg of H9c2 NTEVs, H9c2 DOXEVs,
FL83b NTEVs, FL83b DOXEVs, or an equal volume of the vehicle con-
trol. The conditioned media were collected at 24 h post-treatment.
Since •NO is unstable and completely oxidized in biological fluid, we
measured the accumulation of the stable oxidized products of •NO
—nitrate and nitrite— in the conditioned media using Nitrate/Nitrite
Colorimetric Assay Kit (Cayman, Ann Arbor, MI). Briefly, the condi-
tioned media were incubated with nitrate reductase to convert nitrate
to nitrite. Then, Griess reagents were added to react with total nitrite
and generate a deep purple azo compound. The change in color was
evaluated by reading the absorbance at 540 nm using a microplate
reader (Molecular Devices, San Jose, CA). The concentration of nitrate/
nitrite in samples was calculated from a standard curve generated by
using the known concentration of nitrate.
2.7. Mitochondrial and glycolysis stress test
RAW264.7 cells were seeded into a 96-well plate (Seahorse
Bioscience, North Billerica, MA) at a density of 20,000 cells/well for
both the mitochondrial and glycolysis stress tests. The next day, the
cells were treated with 20 μg/ml of EVs or an equal volume of PBS for
24 h prior to the test. For the mitochondrial stress test, oxygen con-
sumption rate (OCR) was determined using the Seahorse XF-96 ana-
lyzer (Seahorse Bioscience). OCR was measured at baseline (Basal OCR)
followed by the sequential addition of oligomycin (1 μM) to inhibit ATP
synthase, FCCP (1 μM) uncoupler to permeabilize the inner mitochon-
drial membrane and promote maximum electron flow, and rotenone
(1 μM)/antimycin (1 μM) to inhibit complex I and complex III, respec-
tively [36]. ATP-linked OCR was calculated by subtracting the OCR
after oligomycin treatment from the basal OCR. The spare respiratory
capacity was calculated by subtracting the basal OCR from the maximal
OCR after FCCP treatment. For the glycolysis stress test, the extra-
cellular acidification rate (ECAR) was determined by the Seahorse XF-
96 analyzer. ECAR was measured at baseline followed by the sequential
addition of glucose (10mM), Oligomycin (1 μM), and 2-deoxyglucose
(50mM) [37]. Basal glycolysis was calculated by subtracting the ECAR
measurement post-2-deoxyglucose addition from the ECAR measure-
ment post-glucose addition. The glycolytic reserve capacity was calcu-
lated by subtracting the post-oligomycin measurement from the post-
glucose measurement.
2.8. Western blot analysis
Western blot analysis was done in reducing condition. EV suspen-
sion in PBS (0.5 μg/μl) was lysed with RIPA buffer containing protease
inhibitor and sonicated for 3× 30 s using a water sonicator. For wes-
tern blots of macrophage proteins, cells were lysed by incubating with
RIPA buffer containing protease inhibitor on ice for 30min. Protein
concentrations were determined using bicinchoninic acid assay. SDS
polyacrylamide gels (8–15%) were loaded with 50 μg of lysed EVs or
40 μg of whole cell lysates and electrophoresis was performed at 100 V
for 2 h. The proteins were transferred onto nitrocellulose membranes.
After blocking with Odyssey blocking buffer (LI-COR Biosciences,
Lincoln, NE) for 1 h, the membranes were incubated overnight with
primary antibodies at 4 °C. The following primary antibodies were used:
anti-Alix, anti-CD81, anti-HDAC1, anti-Lamin A/C (Santa Cruz
Biotechnology, Dallas, TX), anti-beta actin (Sigma-Aldrich, St. Louis,
MO), anti-MnSOD (Upstate Biotechnology, Waltham, MA), anti-Trx1
(AdipoGen Life Sciences, San Diego, CA). The membranes were washed
three times with TBST buffer and were incubated with IRDye 800 CW
C. Yarana, et al. Redox Biology 26 (2019) 101237
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donkey anti-goat for anti-Alix; donkey anti-rabbit for anti-CD81, anti-
MnSOD, and anti-Trx1; goat anti-mouse for beta-actin, anti-HDAC1,
and anti-Lamin A/C for 1 h at room temperature. After washing three
times, the membranes were air dried and the protein bands were vi-
sualized using the Odyssey scanner (LI-COR).
2.9. NFκB and Nrf-2 DNA binding activity
RAW264.7 cells were seeded at a density of 5×105 cells/well in a 6
well-plate overnight and incubated with FBS-free media supplemented
with 20 μg of H9c2 NTEVs, H9c2 DOXEVs, FL83b NTEVs, FL83b
DOXEVs, or an equal volume of PBS as the vehicle, or Vitamin E (D-α-
Tocopherol succinate, St. Louis, MO) for 24 h. To measure NFκB and
Nrf-2 transcription factor activity, DNA binding ELISA was performed
using TransAM NF-κB and Nrf-2 kits (Active Motif, Carlsbad, CA), ac-
cording to the manufacturer's protocol. Briefly, nuclei from
RAW264.7 cells were extracted by the nuclear extract kit (Active
Motif). The nuclear extract was added onto the oligonucleotide-coated
well and incubated for 1 h. After the washing step, the primary anti-
body for NF-κB (p50) or Nrf-2 was added and incubated for 1 h. Then,
the plates were washed and incubated with horseradish peroxidase-
conjugated secondary antibody for 1 h. The color was developed by the
developing solution and the absorbance was read at 450 nm.
2.10. Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-
PCR)
RNA was isolated from RAW264.7 cells treated with vehicle or EVs
using the MagNA Pure Compact RNA Isolation kit (Roche, Risch-
Rotkreuz, Switzerland). RNA integrity and quantification were eval-
uated using the Agilent 2100 Bioanalyzer System (Santa Clara, CA). The
mRNAs were reverse transcribed to cDNA using the first strand cDNA
Synthesis Kit (Roche). The Nanodrop Spectrophotometer (Thermo
Fisher Scientific) was used to measure cDNA concentration.
Quantitative real-time PCR was performed using a LightCycler 480
Real-Time PCR System (Roche) with gene-specific primers. All primers
were purchased from Invitrogen. Primer sequences for mouse and rat
genes were as follows:
Mouse Tnf 5′-CCTGTAGCCCACGTCGTAGC-3’ (Forward) and.
5′-AGCAATGACTCCAAAGTAGACC-3’ (Reverse)
Mouse Il1b 5′-GCACTACAGGCTCCGAGATGAAC-3’ (Forward) and.
5′-TTGTCGTTGCTTGGTTCTCCTTGT-3’ (Reverse);
Mouse Hmox1 5′-GGTGATGGCTTCCTTGTACC-3′ (Forward) and.
5′-GGTGATGGCTTCCTTGTACC-3′ (Reverse)
Mouse Prdx1 5′-ACACCCAAGAAACAAGGAGGATT-3’ (Forward)
and.
5′-CAACGGGAAGATCGTTTATTGTTA-3’ (Reverse);
Mouse Nqo1 5′-TTCTGTGGCTTCCAGGTCTT-3’ (Forward) and.
5′-AGGCTGCTTGGAGCAAAATA-3’ (Reverse)
Mouse Sod2 5′-ATGTTGTGTCGGGCGGCG-3’ (Forward) and.
5′-AGGTAGTAAGCGTGCTCCCACACG-3’ (Reverse);
Mouse Txnrd1 5′-GGCCAACAAAATCGGTGAACACATGGAAG-3’
(Forward) and.
5′-CGCCAGCAACACTGTGTTAAATTCGCCCT-3’ (Reverse)
Mouse Trx1 5′-ATGGTGAAGCTGATCGAGAGC-3′ (Forward) and.
5′-GGCATATTCAGTAATAGAGGC-3′ (Reverse)
Mouse Actb 5′-TGGAATCCTGTGGCATCCATGAAAC-3’ (Forward)
5′-TAAAACGCAGCTCAGTAACAGTCCG-3’ (Reverse)
Rat Il1b 5′- GCAATGGTCGGGACATAGTT-3’ (Forward)
5′- AGACCTGACTTGGCAGAGGA-3’ (Reverse)
Rat Nos2: 5′-TAGTCAACTACAAGCCCCACG-3’ (Forward)
5′-GTGAGGAACTGGGGGAAACC-3′ (Reverse)
Rat Il10 5′GTTGCCAAGCCTTGTCAGAAA-3’ (Forward)
5′- TTTCTGGGCCATGGTTCTCT-3’ (Reverse)
Rat Actb 5′-AGGCATCCTCACCCTGAAGTA-3’ (Forward)
5′- CACACGCAGCTCATTGTAGA-3’ (Reverse).
The PCR cycle for initial denaturation was 10min at 95 °C. This was
followed by 40 cycles of 15 s at 95 °C, 30 s at 60 °C, and 30 s at 72 °C.
The gene expression levels were calculated by the 2−ΔΔCt method and
the data represent fold change relative to vehicle control.
2.11. Trx1 redox western
Reduced and oxidized forms of Trx1 in nuclear and cytoplasmic
portions of RAW264.7 cells treated with EVs were detected as described
previously [38–40]. After incubation of EVs for 24 h, the cells were
washed with ice-cold PBS and lysed with hypotonic solution supple-
mented with protease inhibitor and 50mM iodoacetic acid (IAA). The
lysate was centrifuged at 16,100 g for 2min and the supernatant was
collected as the cytoplasmic fraction. The nuclear pellets were lysed
with G-lysis buffer supplemented with protease inhibitor and IAA. Io-
doacetic acid (IAA) was used to modify the thiol group, resulting in one
negative charge addition per one modification. Microspin G-25 columns
(GE Healthcare, Chicago, IL) were used to remove excessive IAA. Fifty
μg of derivatized samples were loaded per lane. Trx1 redox forms were
separated by charge using native polyacrylamide gel electrophoresis.
The more negative charge of derivatized Trx1, which indicates the more
reduced Trx1, appear at the lower bands relative to the more oxidized
form [40]. Redox forms of Trx1 were detected using anti-Trx1 antibody
(AdipoGen Life Sciences) as a primary antibody and IRDye® 800CW
donkey anti-Rabbit as a secondary antibody. The protein bands were
visualized using an Odyssey scanner (LI-COR, Lincoln, NE). The band
intensities were assessed using Image Studio 5. x software (LI-COR,
Lincoln, NE).
2.12. Trx activity measurement
Trx activity was measured based on the ability to reduce eosin-la-
beled insulin disulfide, as determined by using a commercial kit
(Cayman Chemical, Ann Arbor, MI) [41]. In brief, EVs-treated or ve-
hicle-treated RAW264.7 cells were washed with ice-cold PBS and col-
lected by cell scraper. After centrifugation at 1000 g for 10min, the
supernatant was discarded, and the pellets were sonicated in 0.2ml TE
buffer and centrifuged at 10,000 g for 20min at 4 °C. Next, 20 μg of cell
lysate were pre-incubated in an assay buffer containing thioredoxin
reductase and NADPH for 30min at 37 °C. Then, eosin-labeled insulin
was added and incubated for 5min at room temperature. Fluorescence
intensity was recorded with excitation/emission spectra of 520/545 nm
every 5min for 1 h. The reduction rate of eosin-labeled insulin was
calculated based on the rate of fluorescence gained per time in the
linear range, and the quantity of active Trx was determined using the
standard curve for known amount of Trx.
2.13. Trx1 overexpression
Open reading frame expression clone of mouse Trx1 with EF1a
promoter in pReceiver-LV233 lentiviral vector was purchased from
GeneCopoeia (Rockville, MD). Empty control vector for pReceiver-
LV233 was used as a negative control for Trx1 overexpression.
Lentiviral production was performed in HEK293T cells, and
RAW264.7 cell transduction was done according to the manufacturer's
protocol. Transduced cells with Trx1 expression vector were selected in
3.0 μg/ml puromycin (Takara Bio USA, Mountain View, CA) containing
media.
2.14. Statistical analysis
Results are presented as the mean ± standard deviation (SD) or
standard error of the mean (SEM), as indicated in the figure legend.
Analysis of variance (ANOVA) was used for comparison of study end-
points including 4HNE slot blot, Western blot, and Trx1 redox western,
EVs, and other parameters in the macrophages from cardiomyocytes
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and hepatocytes. Pairwise comparisons were performed using the
ANOVA model for vehicle versus treated and differences between H9c2
NTEVs vs H9c2 DOXEVs, FL83b NTEVs vs FL83b DOXEVs, H9c2 NTEVs
vs FL83b NTEVs, and H9c2 DOXEVs vs FL83b DOXEVs. Adjusted p-
values due to multiple testings were calculated using the Holm's
method. A value of P < 0.05 was considered significant. The SAS
system version 9.4 was used for data analysis. Excel and GraphPad
Prism were used for graphing.
3. Results
3.1. DOX-treated cardiomyocytes—but not hepatocytes—release EVs with
higher levels of protein-bound 4HNE
Cardiomyocytes are a major target of DOX in vivo. The results of
measuring cell viability after 24 h of DOX treatment show that the
viability of H9c2 cells decreased by 13% while FL83b cell viability was
similar to that of the non-treated control. These data confirm that H9c2
cells are more sensitive to DOX than FL83b cells are (Fig. 1A). The
quantity of EVs, as indicated by the level of EVs protein, reveals that
H9c2 and FL83b cells release equal amounts of EVs per equal number of
cells under normal conditions. DOX caused at least a 4-fold increase in
EVs released from both H9c2 and FL83b cells (Fig. 1B). The presence of
EVs, following isolation by the ExoEasy maxi kit, was validated by
Western blot to detect EVs markers. EVs from non-treated and DOX-
treated H9c2 and FL83b cells contained EVs markers, including Alix (a
protein involved in EV biogenesis) and CD81 (a tetraspanin protein)
(Fig. 1C).
Measurement of 4HNE adduction in equal amounts of EVs protein
reveals that EVs from H9c2 cells had more protein-bound 4HNE than
EVs from FL83b cells. Moreover, comparisons between DOX-treated
EVs (DOXEVs) and non-treated EVs (NTEVs) show that the H9c2
DOXEVs contained more 4HNE adducted proteins than the H9c2 NTEVs
did. However, there was no difference between FL83b DOXEVs and
FL83b NTEVs (Fig. 1D). These data suggest that DOX generates a higher
level of oxidized proteins in cardiomyocyte than in hepatocyte EVs. To
confirm that DOX is responsible for the increased 4HNE in EVs, in-
creasing doses of DOX were used to treat H9c2 cells. The results show a
dose-related increase in 4HNE in EVs derived from the DOX-treated
H9c2 cells (Supplementary Fig. 1).
3.2. Differential effects of H9c2 EVs and FL83 b EVs on macrophage
activation
To investigate the effect of EVs on macrophage function, we de-
termined the levels of pro- and anti-inflammatory cytokines, as well as
•NO production, in conditioned media of RAW264.7 cells treated with
H9c2 NTEVs, H9c2 DOXEVs, FL83b NTEVs, or FL83b DOXEVs for 24 h.
The data show that the release of pro-inflammatory cytokines, in-
cluding TNF alpha, IL-1 beta, IL-6, and •NO, significantly increased in
H9c2 EVs-treated macrophages but not in FL83b EVs-treated macro-
phages (Fig. 2A and D). The •NO generation is specific to nitric oxide
synthase (NOS) because it is suppressible by N(G)-Nitro-L-arginine
methyl ester (L-NAME), which is a competitive inhibitor of NOS
(Fig. 2D). Likewise, anti-inflammatory cytokines such as IL-10 and TGF
beta also increased in response to H9c2 EVs but not FL83 b EV treat-
ment (Fig. 2E and F). These data demonstrate that H9c2 EVs but not
FL83 b EV caused both pro- and anti-inflammatory macrophage acti-
vation. DOX bolstered the immunostimulatory effects of H9c2 EVs but
not FL83 b EV (Fig. 2A and F). The immunostimulatory effect of H9c2
EVs was not due to species differences between rat cardiomyocytes and
mouse macrophages, as similar results were observed in pro- and anti-
inflammatory gene expression in the NR8383 rat macrophage (Fig. 2G
and I).
Fig. 1. Comparison of DOX toxicity, the levels of EVs
and the levels of 4HNE protein adduction in the EVs
released from cardiomyocytes and hepatocytes
(A) Percentage of surviving H9c2 cells and FL83b
cells after 0.5 μM DOX treatment for 24 h (green
bars) compared to non-treated control (black bars).
(B) Amount of EVs released from one million cells of
non-treated H9c2, DOX-treated H9c2, non-treated
FL83b, or DOX-treated FL83b cells. (C)Western blots
of EVs markers: Alix and CD81 in EVs derived from
non-treated H9c2 (H9c2 NTEVs), DOX-treated H9c2
(H9c2 DOXEVs), non-treated FL83b (FL83b NTEVs),
or DOX-treated FL83b (FL83b DOXEVs). (D) The le-
vels of 4HNE protein adduction in H9c2 NTEVs,
H9c2 DOXEVs, FL83b NTEVs, or FL83b DOXEVs.
Data represent the mean of band intensities relative
to H9c2 NTEVs± SD of 5 independent experiments *
p < 0.05. (For interpretation of the references to
color in this figure legend, the reader is referred to
the Web version of this article.)
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3.3. Differential effects of H9c2 EVs and FL83 b EV on macrophage
metabolism
Pro- and anti-inflammatory macrophage functions are supported by
the metabolic process used by macrophages to produce energy [42].
Pro-inflammatory macrophages rely more on glycolysis and less on
mitochondrial respiration. The shift to glycolysis is suitable for rapid
energy production during inflammation. In contrast, anti-inflammatory
macrophages mainly utilize mitochondrial oxidative phosphorylation
metabolism to make the ATP that supports cell survival and tissue re-
pair.
Here, we observed that EVs induce the metabolic shifts in macro-
phages. The data from the mitochondrial stress and glycolytic stress
tests show that EVs from DOX-treated H9c2 cells significantly sup-
pressed basal oxygen consumption rate (OCR) (Fig. 3A and B) and en-
hanced glycolysis of macrophages (Fig. 3D and E), which supports the
metabolic process expected for pro-inflammatory macrophage. EVs
from non-treated H9c2 cells also suppressed basal OCR and slightly, but
not significantly, increased glycolysis. EVs from non-treated and DOX-
treated H9c2 cells had no effect on glycolytic reserve capacity (Fig. 3F).
In contrast to H9c2 EVs, FL83b EVs did not have any effects on basal
OCR, glycolysis, or glycolytic reserve (Fig. 3A and B, 3D-3F), but they
did lead to higher mitochondrial spare respiratory capacity (Fig. 3C).
These data suggest that EVs from hepatocytes did not cause either pro-
or anti-inflammatory macrophage activation. However, their ability to
enhance mitochondrial metabolism suggests that they may prime
macrophages for the tissue repair process when conditions exist that
increase the demand for ATP.
3.4. NFκB and Nrf-2 are activated by H9c2 EVs
Because NFκB and Nrf-2 are sensitive to electrophiles and play an
important role in macrophage activation, we hypothesized that H9c2
EVs, and especially H9c2 DOXEVs, which carry high levels of protein-
bound 4HNE, might activate both NFκB and Nrf-2, leading to the ob-
served pro- and anti-inflammatory macrophage activation.
By measuring the DNA binding activity of NFκB and Nrf2 in
RAW264.7 macrophages treated with EVs, we found that H9c2 NTEVs
significantly enhanced NFκB and Nrf-2 DNA binding activity. H9c2
DOXEVs slightly enhanced higher NFκB and Nrf-2 activation compared
to H9c2 NTEVs (Fig. 4A and B). Interestingly, neither FL83b NTEVs nor
FL83b DOXEVs significantly activated NFκB or Nrf-2 activity. The
transcriptional activities of NFκB and Nrf-2 were confirmed by the ex-
pression of their target genes: TNF alpha (Tnf) and interleukin-1 beta
(Il1b) for the former (Fig. 4C and D), and heme oxygenase 1 (Hmox-1)
and peroxiredoxin 1 (Prdx1) for the latter (Fig. 4E and F).
To verify that 4HNE adduction is responsible for immune activation
of H9c2-derived EVs via NFκB and Nrf2 pathways, we co-treated
RAW264.7 macrophages with 20 μg of H9c2 DOXEVs and various
concentrations of vitamin E, a known lipid antioxidant that prevents
polyunsaturated fatty acids from free radical attacks [43]. The results
show that vitamin E inhibits NFκB and Nrf-2 responses in a dose-de-
pendent manner with a greater inhibition effect on NF-kB than Nrf-2 at
the same concentration (Supplementary Figs. 2A–2B).
To investigate why FL83b EVs, which also contain 4HNE-adducted
proteins, did not activate NFκB or Nrf-2, we measured the mRNA levels
of several antioxidants, including NAD(P)H Quinone Dehydrogenase 1
(Nqo1), superoxide dismutase 2 (Sod2), thioredoxin reductase 1
(Txnrd1), and Trx1, that might suppress the effect of FL83b EVs on
macrophage activation (Supplementary Figs. 3A–3D). Interestingly,
among these antioxidant genes, Trx1 is the gene that was upregulated
by FL83b EVs, especially FL83b DOXEVs treatment (Supplementary
Fig. 3D), suggesting that Trx1 may play an important role in preventing
the activation of macrophages.
3.5. Trx1 function is critical for the differential effects of H9c2 EVs and
FL83b EVs on macrophage activation
The redox status of Trx1 is important for its antioxidant activity and
its immunoregulatory function. First, we evaluated the redox status of
Trx1 in cytoplasmic and nuclear fraction of RAW264.7 macrophages in
response to EVs treatment. The purity of cytoplasmic and nuclear
fractions was verified by Western blot (Fig. 5A).
Next, we determined the redox status of Trx1 by redox western
analysis. The results show that H9c2 NTEVs-treated macrophages have
lower levels of reduced Trx1 in the cytoplasm compared to the vehicle-
treated control (though not statistically significant) and that treatment
with H9c2 DOXEVs significantly lowered the reduced Trx1. In contrast,
FL83b DOXEVs significantly increased the cytoplasmic levels of re-
duced Trx1. Macrophages treated with FL83b NTEVs also increased
cytoplasmic reduced Trx1, but levels did not reach statistical sig-
nificance (Fig. 5B and D). In the nuclear compartment, only the reduced
form of Trx1 was detected and there was no significant change after EVs
treatment (Fig. 5C and E). The changes in Trx1 activity in cytoplasm
and nucleus are consistent with the levels of reduced Trx1 (Fig. 5F and
G). These data suggest that EVs exert their effect on Trx1 redox state
mainly in the cytoplasm of macrophages. The sharp contrast between
the reduced Trx1 levels in cytoplasm of H9c2 DOXEVs-treated cells and
FL83b DOXEVs-treated cells highlights the significance of Trx1 activity
in macrophage activation.
3.6. Trx1 at the center of the NFkB/Nrf-2 axis
To validate the role of Trx1 on EVs-mediated macrophage activation
through NFκB and Nrf-2 pathways, we overexpressed mouse Trx1 gene
in RAW264.7 cells. We then compared the DNA binding activity of
NFκB and Nrf-2 24 h after EVs treatment. As shown in Fig. 6A, we
confirmed that the level of Trx1 did increase in overexpressed cells.
Trx1 redox western analysis in cytoplasmic and nuclear fraction shows
that both reduced and oxidized Trx1 increased in Trx1 overexpressed
cells. In nuclear fraction, reduced Trx1 was more predominant than
oxidized Trx1 (Fig. 6B). Trx1 overexpression suppressed the effect of
H9c2 NTEVs and H9c2 DOXEVs on NFκB and Nrf-2 activities, causing a
reduction approximating that of the vehicle-treated control. The in-
hibitory effect of Trx1 was more prominent in H9c2 DOXEVs-treated
cells, where NFκB and Nrf-2 activities decreased to the same levels as in
the H9c2 NTEVs-treated cells (Fig. 6C and D). As a target gene of NFκB,
Tnf in H9c2 DOXEVs-treated cells was significantly downregulated by
Fig. 2. Cardiomyocyte-derived EVs but not hepatocyte-derived EVs promote both pro-inflammatory and anti-inflammatory cytokine release as well as nitric oxide
production by macrophages. The effect was potentiated by DOX treatment
(A-C) Levels of pro-inflammatory cytokines TNF alpha, IL-1 beta, IL-6 in RAW264.7 cells treated for 24 h with vehicle, H9c2 NTEVs, H9c2 DOXEVs, FL83b NTEVs, or
FL83b DOXEVs. (D) Level of Nitrite/Nitrate as a parameter of •NO production in RAW264.7 cells treated with vehicle, H9c2 NTEVs, H9c2 DOXEVs, FL83b NTEVs, or
FL83b DOXEVs. L-NAME was used as a negative control as it is the inhibitor of •NO production. (E–F) Levels of anti-inflammatory cytokines; IL-10 and TGF beta in
RAW264.7 cells treated for 24 h with vehicle, H9c2 NTEVs, H9c2 DOXEVs, FL83b NTEVs, or FL83b DOXEVs. Data represent the mean ± SD of 4 independent
experiments, *p < 0.05 vs vehicle control, #p < 0.05 vs H9c2 NTEVs. (G–I) Gene expression of NR8383 rat macrophages after EVs treatment. Bar graphs represent
fold change of Il1b (G), Nos2 (H) and Il10 (I) gene expression measured by RT-PCR of NR8383 rat macrophages treated with vehicle, H9c2 NTEVs, H9c2 DOXEVs,
FL83b NTEVs, or FL83b DOXEVs. Data represent the mean ± SD of 3 independent experiments, *p < 0.05 vs vehicle, #p < 0.05 vs H9c2 NTEVs.
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Trx1. Tnf in H9c2 NTEVs-treated Trx1 overexpressed cells was slightly
but not significantly lower than in the empty vector control. However,
Trx1 overexpression significantly downregulated Tnf in H9c2 DOXEVs-
treated cells (Fig. 6E). In H9c2 DOXEVs-treated cells, Hmox1, an Nrf-2
target gene, was also suppressed by Trx1 overexpression (Fig. 6F).
These data support the central role of Trx1 in regulating both the NFκB
and Nrf-2 pathways.
4. Discussion
In this study, we demonstrate that cardiomyocytes with a high
sensitivity to DOX release EVs containing oxidized molecules that
Fig. 3. Differential effects of H9c2 EVs and FL83b
EVs on mitochondrial respiration and glycolysis
(A) Kinetic graph of OCR at baseline and after oli-
gomycin, FCCP, and rotenone/antimycin treatment
of macrophages incubated with vehicle, H9c2
NTEVs, H9c2 DOXEVs, FL83b NTEVs, or FL83b
DOXEVs. (B) Bar graph represents the average of
basal OCR calculated from graph A. (C) Bar graph
represents the average of Spare Respiratory Capacity
calculated from graph A. (D) Kinetic graph of ECAR
at baseline and after glucose, oligomycin, and 2-
deoxyglucose (2-DG) treatment of macrophages in-
cubated with vehicle, H9c2 NTEVs, H9c2 DOXEVs,
FL83b NTEVs, or FL83b DOXEVs. (E) Bar graph re-
presents the average of basal glycolysis calculated
from graph D. (F) Bar graph represents the average
of glycolytic reserve calculated from graph D. Data
represent the mean ± SEM of 3 independent ex-
periments, *p < 0.05 vs vehicle.
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activate the pro- and anti-inflammatory responses of macrophages. In
contrast, hepatocytes with a high tolerance to DOX release EVs that do
not have immunological effects. This differential effect of EVs on
macrophage functions is regulated by the redox state of Trx1, which
influences the NFκB and Nrf-2 pathways.
DOX is a highly effective chemotherapeutic agent that is well-
known to cause redox cycling in vivo. Our previous study demonstrates
that heart and liver are two major normal tissue targets of DOX that
release EVs into the circulation [19]. The results from this study of
cardiomyocytes and hepatocytes are consistent with the animal data
and supportive of the premise that cardiomyocytes and hepatocytes
contribute to EVs released in response to DOX treatment. The higher
levels of 4HNE-adducted proteins in H9c2-derived EVs, which increased
after DOX treatment, might be due to cardiomyocytes being more
susceptible to oxidative stress than hepatocytes are, since the activities
of catalase, superoxide dismutase, and glutathione peroxidase in the
heart are 150 times, 4 times, and 27 times lower than those in the liver,
respectively [21,44].
Oxidized phospholipids are known to induce or inhibit inflammation.
It has been shown that when macrophages are treated with oxidized 1-
palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (OxPAPC), which
is a major component of low-density lipoproteins, they are stimulated to
express both pro- and anti-inflammatory phenotypes called Mox mac-
rophages. Mox macrophages are a redox-regulatory phenotype with a
high capacity to withstand oxidative stress by upregulating anti-oxidant
enzymes through Nrf-2 activation [45]. Mox macrophages contribute to
30% of macrophages found in atherosclerotic plaque in a mouse model
and play a key role in promoting chronic low-grade inflammation [46].
Since we observed that EVs from cardiomyocytes contain 4HNE, which is
an oxidized lipid product, and because Nrf-2 activation also occurred, it
is tempting to speculate that Mox may be the macrophage phenotype
induced by cardiomyocyte EVs. However, extensive studies will be
needed to substantiate the presence of Mox in immune responses. In our
system, cardiomyocytes released oxidized EVs and stimulated an innate
immune cell response without DOX treatment, which is unlikely to occur
in vivo. This in vitro observation may be due, in part, to the cells being
exposed to 21% O2 in the cell culture system, which is higher than the
4–14% O2 concentration in tissue. The higher concentration of oxygen
caused oxidative stress to the cells at baseline [47]. By contrast, this O2
concentration is a negligible issue for hepatocytes since they contain high
levels of antioxidant enzymes. A comparison of the non-treated and DOX-
treated cells shows that DOX promoted release of immunostimulatory
EVs from cardiomyocytes but not hepatocytes. This effect is not likely
due to DOX, since the drug had been removed during the washing step.
Our in vitro model mimics the clinical scenario where cardiotoxicity oc-
curs later, after the cessation of DOX treatment [48]. A low-level but
persistent inflammation, mediated by macrophage activation that is
caused by cardiomyocyte-derived EVs, could lead to impaired cardiac
function and systemic inflammation that can also affect indirect targets
of DOX, such as brain. Although the hepatocytes-derived EVs contained
fewer 4HNE-adducted proteins than the cardiomyocytes-derived EVs,
there were some HNE-adducted proteins in the hepatocyte EVs. How-
ever, only the H9c2-derived EVs but not the FL83b-derived EVs activated
macrophages. Therefore, the FL83b EVs may activate some genes, which
Fig. 4. Cardiomyocyte-derived EVs but not hepatocyte-derived EVs enhanced NFκB and Nrf-2 transcription factor activities. The effect was potentiated by DOX
(A) NFkB DNA binding activity and (B) Nrf2 DNA binding activity in macrophages treated with vehicle, H9c2 NTEVs, H9c2 DOXEVs, FL83b NTEVs, or FL83b
DOXEVs. (C, D) Fold change of pro-inflammatory cytokines TNF alpha and IL-1 beta gene expression. (E, F) Fold change of anti-oxidant enzymes Hmox1 and Prdx1
gene expression after 24 h treatment of RAW264.7 cells with vehicle, H9c2 NTEVs, H9c2 DOXEVs, FL83b NTEVs, or FL83b DOXEVs. Data represent the mean ± SD
of 3 independent experiments, *p < 0.05 vs vehicle, #p < 0.05 vs H9c2 NTEVs.
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prevents macrophage stimulation. Antioxidants have been shown to in-
hibit EV-associated 4HNE adduction. We have previously demonstrated
that treatment with an antioxidant such as Mn(III) meso-tetrakis (N-(n-
butoxyethyl)pyridium-2-yl)porphyrin, MnTnBuOE-2-PyP5+ (MnP) de-
creased 4HNE adduction in serum EVs in animals [19]. However, whe-
ther blocking 4HNE-adducted EVs alone is sufficient to block the activity
of NF-kB and Nrf-2 would need to be investigated in depth as we found
4HNE-adducted proteins in the EVs. Thus, future investigation should
focus on this and how HNE-adducted proteins contribute to EVs effects
on the signaling pathways.
Metabolic reprogramming provides substrates needed for macro-
phage function. In our study, macrophages treated with cardiomyocyte
DOXEVs suppressed mitochondrial oxidative phosphorylation
(OXPHOS) and promoted glycolysis. This metabolic shift provides the
environment required for antioxidant synthesis to maintain redox
homeostasis [49]. In contrast to cardiomyocyte DOXEVs, hepatocyte
DOXEVs did not have any effects on basal OXPHOS or glycolysis, but
they did induce higher reserve capacity. Mitochondrial reserve capacity
indicates the ability of mitochondria to generate ATP under high energy
demand conditions, which is critical for the tissue repair process [50].
Our data suggest it is possible that, following DOX treatment, hepato-
cytes release EVs that provide biomolecules to help prepare macro-
phages for an anti-inflammatory response and thus help with the sub-
sequent tissue repair. We propose that one of the key biomolecules is
Trx1, because we found that Trx1 was the only major antioxidant en-
zyme that showed an increase in macrophages treated with hepatocyte
EVs but a decrease in cardiomyocyte EVs. In heart tissue, Trx1 is known
to enhance mitochondrial function by upregulation of genes that are
involved in mitochondrial OXPHOS, including cytochrome c oxidase
[51]. Trx1 also can help to maintain mitochondrial function by pre-
serving the activity of the mTOR pathway [52]. In macrophages, Trx1
enhances the upregulation of IL-10 and CD206, the two genes com-
monly expressed in anti-inflammatory macrophages [53]. It is possible
that, in macrophages that promote tissue healing, EVs-driven Trx1 ex-
pression may be a mechanism that protects the liver against indirect
tissue damage by DOX.
Trx1 plays a major role in regulating NFκB and Nrf-2 activities,
which depend on redox state and localization. In our model, the change
in Trx1 redox state occurred predominantly in cytoplasm. Thus, our
data suggest that cytosolic Trx1 is a key to EVs-mediated macrophage
Fig. 5. Differential effects of H9c2 EVs and
FL83b EVs on reduced Trx1 and Trx1 ac-
tivity
(A) Verification of cytoplasmic and nuclear
fraction purification by Western blot of
manganese superoxide dismutase (MnSOD)
and beta actin for cytoplasmic fraction, as
well as histone deacetylase 1 (HDAC1) and
lamin A/C for nuclear fraction. (B and C)
Redox western of Trx1 in cytoplasmic frac-
tion (B) and nuclear fraction (C) of
RAW264.7 treated with vehicle, H9c2
NTEVs, H9c2 DOXEVs, FL83b NTEVs, or
FL83b DOXEVs. (D and E) Bar graph shows
the average fold change (n=3) of reduced
Trx1 levels in cytoplasm (D) and nuclei (E).
(F and G) Trx1 activity from equal amounts
of protein in cytoplasm (F) and nuclei (G) of
RAW264.7 treated with vehicle, H9c2
NTEVs, H9c2 DOXEVs, FL83b NTEVs, or
FL83b DOXEVs, *p < 0.05 vs vehicle,
#p < 0.05 vs H9c2 NTEVs.
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activation. However, we could not completely rule out the role of nu-
clear Trx1. We propose that the low level of the reduced Trx1 in cy-
toplasm caused by cardiomyocyte DOXEVs treatment leads to the low
ability to sequester NFκB and Nrf-2 by IκB and Keap-1, respectively,
resulting in the activation of these transcription factors. In contrast to
cardiomyocyte EVs, hepatocyte EVs increase the level of reduced cy-
toplasmic Trx1 leading to a lack of macrophage activation (Fig. 7). Trx1
overexpression causes higher levels of Trx1 in both cytoplasm and in
nucleus. Trx1 in cytoplasm inhibits both NFκB and Nrf-2 activation
while Trx1 in nucleus promotes NFκB and Nrf-2 activities. In Trx1-
overexpressed cells, increased cytoplasmic Trx1 might not be high en-
ough to completely block NFκB and Nrf-2 nuclear translocation. Con-
sequently, the translocated NFκB and Nrf-2 transcription activities will
be enhanced by higher levels of nuclear Trx1. Therefore, the effect of
H9c2 EVs is still significantly higher than vehicle and/or mouse hepa-
tocytes.
In conclusion, our data suggest that not all EVs released upon ex-
posure to pro-oxidant conditions are detrimental. EVs released by cells
that survive oxidative stress can induce macrophages to generate more
redox regulatory proteins, such as Trx1, that help limit immune acti-
vation. Therefore, preventing the release of EVs by interfering with EVs
biogenesis will not only block the ability of injured cells to remove toxic
molecules, it also eliminates any beneficial effects of EVs released by
surviving cells. Consequently, modulation of Trx1 function could be an
effective approach to modulate the innate immune system to protect
against the indirect effects of inflammatory mediators following cancer
therapy.
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Fig. 6. Trx1 overexpression suppressed the
effect of H9c2 EVs on macrophage activa-
tion via NFκB and Nrf-2
(A) Western blot of Trx1 in RAW264.7
macrophage with Trx1 overexpression
compared to empty vector. (B) Redox wes-
tern of Trx1 in cytoplasmic and nuclear
fraction of RAW264.7 macrophage with
Trx1 overexpression compared to empty
vector. (C and D) NFkB DNA binding ac-
tivity (C) and Nrf2 DNA binding activity (D)
in empty vector (blue) and Trx1 over-
expressed RAW264.7 macrophages (orange)
treated with vehicle, H9c2 NTEVs, H9c2
DOXEVs, FL83b NTEVs, or FL83b DOXEVs.
(E and F) Fold change of pro-inflammatory
cytokines Tnf (C) anti-oxidant Hmox1 (D)
gene expression after 24 h treatment of
empty vector or Trx1 overexpressed
RAW264.7 cells treated with vehicle, H9c2
NTEVs, H9c2 DOXEVs, FL83b NTEVs, or
FL83b DOXEVs. Data represent the
mean ± SD of 3 independent experiments,
*p < 0.05 vs empty vector + vehicle,
#p < 0.05 vs empty vector + H9c2
NTEVs, ‡p < 0.05 vs Trx1 over-
expression + vehicle, $ p < 0.05 vs empty
vector with the same treatment. (For inter-
pretation of the references to color in this
figure legend, the reader is referred to the
Web version of this article.)
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